Current treatment options in systemic Sclerosis (Scleroderma).
Systemic Sclerosis (SSc) or Scleroderma is a generalized autoimmune disease with variable involvement of the skin and major organs. Etiology and pathogenesis are still largely unknown, but a variety of humoral and cellular autoimmune phenomena can be observed, and a pivotal role of T lymphocytes in SSc pathogenesis is postulated. The rarity of the disease, the wide spectrum of clinical manifestations and severity as well as a variable course render therapy in SSc a major challenge. In view of the immunopathogenesis of SSc, many (presumed) immunomodulatory agents have been used, but no single agent has been proven to be convincingly effective. Trials with extracorporeal therapies (such as photopheresis, plasmapheresis) or even stem cell transplantation are in progress. In contrast to the hitherto unsuccessful therapeutic approaches for the overall disease course, some life-threatening organ manifestations can often be treated successfully, e.g. interstitial pneumonitis with i.v. cyclophosphamide and scleroderma renal crisis with ACE inhibitors and haemodialysis, respectively. Furthermore, pharmacological and supportive treatment of Raynaud's phenomenon and gastrointestinal involvement can alleviate the burden of the disease. Current therapeutic options as well as hitherto investigated immunomodulators are reviewed in this article.
Stummvoll
G H
GH
Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna. Georg.Stummvoll@akh-wien.ac.at
D018501:Antirheumatic Agents / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000209:etiology; D010396:Penicillamine / Q000627:therapeutic use*; D010789:Phototherapy; D010956:Plasmapheresis; D011928:Raynaud Disease / Q000209:etiology; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology
D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D010396:Penicillamine